• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较有和无逼尿症妇女的膀胱壁血管化和整体灌注。

Comparison of vascularization and overall perfusion of the bladder wall between women with and without overactive bladder syndrome.

机构信息

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan.

Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.

出版信息

Sci Rep. 2020 May 5;10(1):7549. doi: 10.1038/s41598-020-64532-0.

DOI:10.1038/s41598-020-64532-0
PMID:32371952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7200738/
Abstract

The pathophysiology of female overactive bleeder syndrome (OAB) remains undetermined. Our aim is to elucidate the role of vacularization and overall perfusion of the bladder wall in women with OAB. Between 2010 and 2016, women with OAB and the asymptomatic controls were enrolled. Women with OAB were treated with tolterodine. Women with OAB (n = 40) had higher vascularization index (0.40 ± 0.57 versus 0.17 ± 0.22, p = 0.003), vascularization-flow index (0.15 ± 0.28 versus 0.05 ± 0.08, p = 0.003) and thicker trigone (0.56 ± 0.13 cm versus 0.47 ± 0.11 cm, p = 0.004), compared with the controls (n = 34). The following optimum cut-off values to predict OAB were determined: (1) vascularization index (%) ≥ 0.16, (2) vascularization-flow index ≥ 0.032, and (3) trigone bladder wall thickness ≥ 0.47 cm with an area under the curve of 0.71, 0.71 and 0.70, respectively. Correlation analysis showed that a significant correlation between urgency and vascularization index/vascularization-flow index (Spearman's rho = 0.34 and 0.35, respectively, all p < 0.01). However, after 12 weeks of tolterodine treatment, the vascularization index, flow index and vascularization-flow index did not differ between baseline and after treatment. In conclusion, women with OAB have higher vascularization and overall perfusion of the bladder wall, compared women without OAB. However, vascularization and overall perfusion did not change after antimuscarinic treatment.

摘要

女性过度活动性膀胱综合征(OAB)的病理生理学仍未确定。我们的目的是阐明血管化和膀胱壁整体灌注在 OAB 女性中的作用。2010 年至 2016 年间,招募了 OAB 女性和无症状对照者。OAB 女性接受托特罗定治疗。OAB 女性(n=40)的血管化指数(0.40±0.57 比 0.17±0.22,p=0.003)、血管化-血流指数(0.15±0.28 比 0.05±0.08,p=0.003)和三角区厚度(0.56±0.13cm 比 0.47±0.11cm,p=0.004)均高于对照组(n=34)。确定了预测 OAB 的最佳截断值:(1)血管化指数(%)≥0.16,(2)血管化-血流指数≥0.032,(3)三角区膀胱壁厚度≥0.47cm,曲线下面积分别为 0.71、0.71 和 0.70。相关性分析显示,急迫性与血管化指数/血管化-血流指数之间存在显著相关性(Spearman's rho 分别为 0.34 和 0.35,均 p<0.01)。然而,托特罗定治疗 12 周后,基线和治疗后血管化指数、血流指数和血管化-血流指数无差异。总之,与无 OAB 女性相比,OAB 女性的膀胱壁血管化和整体灌注更高。然而,抗毒蕈碱治疗后血管化和整体灌注没有改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa2/7200738/4c49c2cc0dc3/41598_2020_64532_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa2/7200738/262e0c05bd02/41598_2020_64532_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa2/7200738/242686491141/41598_2020_64532_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa2/7200738/4c49c2cc0dc3/41598_2020_64532_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa2/7200738/262e0c05bd02/41598_2020_64532_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa2/7200738/242686491141/41598_2020_64532_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa2/7200738/4c49c2cc0dc3/41598_2020_64532_Fig3_HTML.jpg

相似文献

1
Comparison of vascularization and overall perfusion of the bladder wall between women with and without overactive bladder syndrome.比较有和无逼尿症妇女的膀胱壁血管化和整体灌注。
Sci Rep. 2020 May 5;10(1):7549. doi: 10.1038/s41598-020-64532-0.
2
Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects.女性膀胱过度活动症患者的自主神经功能障碍和动脉僵硬度以及抗毒蕈碱药物的相关影响。
Maturitas. 2014 Sep;79(1):65-9. doi: 10.1016/j.maturitas.2014.06.001. Epub 2014 Jun 20.
3
Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study.托特罗定 ER 可降低膀胱过度活动症女性的膀胱壁厚度增加。一项随机、安慰剂对照、双盲、平行组研究。
Neurourol Urodyn. 2018 Jan;37(1):237-243. doi: 10.1002/nau.23281. Epub 2017 Apr 13.
4
Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.Vibegron(RVT-901/MK-4618/KRP-114V)每日一次单药治疗或与托特罗定联合治疗膀胱过度活动症患者的多中心、IIb 期、随机、双盲、对照试验。
Eur Urol. 2019 Feb;75(2):274-282. doi: 10.1016/j.eururo.2018.10.006. Epub 2018 Oct 25.
5
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.非索罗定与托特罗定缓释片治疗膀胱过度活动症的疗效比较:男女患者的疗效比较。
BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.
6
A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.一项比较托特罗定与加重型阴道球囊在膀胱过度活动症女性患者中应用效果的前瞻性随机试验。
Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:91-7. doi: 10.1016/j.ejogrb.2015.11.034. Epub 2015 Dec 2.
7
Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.托特罗定缓释剂对患者膀胱状况认知及膀胱过度活动症症状的影响*
Curr Med Res Opin. 2008 Dec;24(12):3513-21. doi: 10.1185/03007990802537122.
8
Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.女性膀胱过度活动症及抗毒蕈碱药物相关效应的心理测量评估
Maturitas. 2014 Dec;79(4):428-34. doi: 10.1016/j.maturitas.2014.08.009. Epub 2014 Sep 3.
9
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.在有膀胱过度活动症的老年和年轻受试者中,非索罗定与托特罗定的疗效和耐受性:两项安慰剂对照试验的事后汇总分析。
Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.
10
Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.随机、开放标签、托特罗定对照、新型抗毒蕈碱药物伊米苷净治疗膀胱过度活动症患者的比较研究。
Neurourol Urodyn. 2019 Jun;38(5):1313-1321. doi: 10.1002/nau.23980. Epub 2019 Mar 19.

引用本文的文献

1
Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives.膀胱过度活动症的病理生理学及包括β3肾上腺素能受体激动剂在内的药物治疗——基础研究视角
Int Neurourol J. 2024 Feb;28(Suppl 1):12-33. doi: 10.5213/inj.2448002.001. Epub 2024 Feb 29.

本文引用的文献

1
Posterior tibial nerve stimulation for treating neurologic bladder in women: a randomized clinical trial.胫后神经刺激治疗女性神经源性膀胱:一项随机临床试验。
Acta Med Iran. 2014;52(11):816-21.
2
Overactive bladder and its effects on sexual dysfunction among women.女性膀胱过度活动症及其对性功能障碍的影响。
Acta Obstet Gynecol Scand. 2013 Oct;92(10):1202-7. doi: 10.1111/aogs.12203.